BioCentury | Feb 19, 2020
Finance

Feb. 19 Financial Quick Takes: bluebird's delayed BLA timeline, plus fundings for NeoTx, Scipher and EnClear

bluebird sheds value after pipeline update  Shares of bluebird bio Inc. (NASDAQ:BLUE) dipped $7.77 to $80.45 Wednesday, lopping off about $430 million of the company's market cap, after the company extended the BLA timeline for...
BioCentury | Jan 31, 2020
Product Development

CSL is harnessing its supply chain expertise to expand into cell and gene therapy

CSL aims to leverage the logistics expertise it built through its plasma business to expand into cell and gene therapy. The company has a sickle cell disease program in Phase I and is lining up...
BioCentury | Jan 18, 2020
Product Development

Mapping the path to gene therapy 2.0

A series of incremental but important improvements on the existing gene therapies are starting to address some of the technology’s key limitations. But some argue it will take a major overhaul of manufacturing practices to...
BC Extra | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
BioCentury | Jan 1, 2020
Regulation

Fewer FDA approvals in 2019, but a basket of firsts

While the year held fewer approvals of new molecular entities than 2018, it was not short of major achievements. FDA greenlit several drugs with innovative modalities, against novel targets and for diseases that have long...
BioCentury | Dec 14, 2019
Product Development

BCMA programs begin to find their niches

As CAR Ts, bispecifics and ADCs targeting BCMA battle it out in multiple myeloma, the question is not which modality will win, but whether they can fill different niches in the treatment landscape. The safety...
BC Extra | Dec 11, 2019
Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

ElevateBio LLC hired Melissa Carpenter as CSO of regenerative medicine, a new position. She was president of her own stem cell research consulting firm. ElevateBio emerged from stealth in May with $150 million in series...
BC Extra | Dec 10, 2019
Clinical News

ASH sets up multiple anti-BCMA opportunities for MM patients

BCMA-targeted agents to treat multiple myeloma once again took center stage at ASH as more companies and modalities continue to pile into the space, setting up several options for patients and physicians based on trade-offs...
BC Extra | Nov 19, 2019
Clinical News

Vertex, CRISPR show early benefits with therapy, but longer term data are needed to show how it stacks up

Vertex and partner CRISPR Therapeutics showed sustained benefits in the first two patients treated with their CTX001, but longer term data will be needed to understand how the ex vivo CRISPR therapy stacks up against...
BC Extra | Nov 18, 2019
Company News

Novo enters RNAi via liver disease deal with Dicerna

As Novo continues to remake its R&D, it is adding RNAi technology to its toolkit though a liver-focused deal with Dicerna. The partners will use Dicerna's GalXC platform to explore more than 30 liver cell...
Items per page:
1 - 10 of 354
BioCentury | Feb 19, 2020
Finance

Feb. 19 Financial Quick Takes: bluebird's delayed BLA timeline, plus fundings for NeoTx, Scipher and EnClear

bluebird sheds value after pipeline update  Shares of bluebird bio Inc. (NASDAQ:BLUE) dipped $7.77 to $80.45 Wednesday, lopping off about $430 million of the company's market cap, after the company extended the BLA timeline for...
BioCentury | Jan 31, 2020
Product Development

CSL is harnessing its supply chain expertise to expand into cell and gene therapy

CSL aims to leverage the logistics expertise it built through its plasma business to expand into cell and gene therapy. The company has a sickle cell disease program in Phase I and is lining up...
BioCentury | Jan 18, 2020
Product Development

Mapping the path to gene therapy 2.0

A series of incremental but important improvements on the existing gene therapies are starting to address some of the technology’s key limitations. But some argue it will take a major overhaul of manufacturing practices to...
BC Extra | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
BioCentury | Jan 1, 2020
Regulation

Fewer FDA approvals in 2019, but a basket of firsts

While the year held fewer approvals of new molecular entities than 2018, it was not short of major achievements. FDA greenlit several drugs with innovative modalities, against novel targets and for diseases that have long...
BioCentury | Dec 14, 2019
Product Development

BCMA programs begin to find their niches

As CAR Ts, bispecifics and ADCs targeting BCMA battle it out in multiple myeloma, the question is not which modality will win, but whether they can fill different niches in the treatment landscape. The safety...
BC Extra | Dec 11, 2019
Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

ElevateBio LLC hired Melissa Carpenter as CSO of regenerative medicine, a new position. She was president of her own stem cell research consulting firm. ElevateBio emerged from stealth in May with $150 million in series...
BC Extra | Dec 10, 2019
Clinical News

ASH sets up multiple anti-BCMA opportunities for MM patients

BCMA-targeted agents to treat multiple myeloma once again took center stage at ASH as more companies and modalities continue to pile into the space, setting up several options for patients and physicians based on trade-offs...
BC Extra | Nov 19, 2019
Clinical News

Vertex, CRISPR show early benefits with therapy, but longer term data are needed to show how it stacks up

Vertex and partner CRISPR Therapeutics showed sustained benefits in the first two patients treated with their CTX001, but longer term data will be needed to understand how the ex vivo CRISPR therapy stacks up against...
BC Extra | Nov 18, 2019
Company News

Novo enters RNAi via liver disease deal with Dicerna

As Novo continues to remake its R&D, it is adding RNAi technology to its toolkit though a liver-focused deal with Dicerna. The partners will use Dicerna's GalXC platform to explore more than 30 liver cell...
Items per page:
1 - 10 of 354